代谢功能和CD147治疗血液恶性瘤的治疗潜力:概述
Isabella Spinello1, Catherine Labbaye1, Ernestina Saulle1
1Istituto Superiore di Sanità, National Center for Drug Research and Evaluation, 00161 Rome, Italy.
International journal of molecular sciences
|September 14, 2024
概括
针对参与代谢重编程的蛋白质CD147,为治疗白血病和多发性骨髓瘤等血液恶性瘤提供了一个有希望的新策略,可能克服药物耐药性.
科学领域:
- 在瘤学瘤学.
- 癌症新陈代谢 癌症新陈代谢
- 血液学 血液学 血液学
背景情况:
- 血液性恶性瘤是血液形成组织的多种癌症,其特点是代谢适应和免疫逃逸,有助于治疗耐药性.
- CD147 (也称为EMMPRIN或Basigin) 涉及各种癌症的代谢重编程,包括血液性恶性瘤.
研究的目的:
- 为了探索血液恶性瘤中CD147的代谢功能.
- 研究CD147对瘤微环境和疾病进展的影响.
- 突出CD147作为血液癌症的潜在治疗点.
主要方法:
- 关于CD147在癌症代谢中的作用的文献综述.
- 分析CD147与代谢调节蛋白的相互作用.
- 探索CD147对瘤微环境和瘤转变的影响.
主要成果:
- CD147的过度表达驱动了血液癌细胞中的代谢转化.
- CD147与单碳酸盐载体和葡萄糖载体1等关键蛋白质相互作用,调解信号传递,生长和转移.
- CD147显著影响瘤微环境,影响白血病,骨髓瘤和淋巴瘤.
结论:
- CD147在血液恶性瘤的代谢适应和进展中发挥着关键作用.
- 向CD147为改善血液癌症患者治疗结果提供了一个新的治疗途径.
相关概念视频
Regulation of Hematopoietic Stem Cells
3.4K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
3.4K
Mesenchymal Stem Cells
4.5K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
4.5K


